Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the pharmacokinetics of risperidone in a group of
pediatric patients with Pervasive Developmental Disorder (PDD). The study will determine how
much risperidone and its breakdown product, 9-hydroxy-risperidone, is in the blood following
the patient's usual daily dose. The study is designed to look at how fast children absorb,
breakdown, and eliminate risperidone.